Pharmacokinetic-and pharmacodynamic-based antithrombotic dosing recommendations in children

Expert Review of Clinical Pharmacology

Volumn 5, Issue 4, 2012, Pages 389-396

  Har Ko, Richard ^a   Young, Guy ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

anticoagulation; children; pharmacodynamics; pharmacokinetics

Indexed keywords

ANTICOAGULANT AGENT; ARGATROBAN; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; REVIPARIN; TINZAPARIN;

ANTICOAGULATION; AREA UNDER THE CURVE; BODY SURFACE; CHILD CARE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; HEMOSTASIS; HUMAN; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; REVIEW; VENOUS THROMBOEMBOLISM;

ADULT; AGE FACTORS; ANTICOAGULANTS; BODY SURFACE AREA; BODY WEIGHT; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; FIBRINOLYTIC AGENTS; HEMOSTASIS; HUMANS; INFANT; INFANT, NEWBORN; PRACTICE GUIDELINES AS TOPIC; VENOUS THROMBOEMBOLISM;

EID: 84866135815     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.12.23     Document Type: Review

References (32)

1. Raffini L, Huang YS, Witmer C, Feudtner C. Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007. Pediatrics 124(4), 1001-1008
2. Crafoord C. Heparin and postoperative thrombosis. Acta. Chem. Scand. A. 82, 319-323 (1939).
3. Butt HR, Allen EU, Bollman JL. A preparation from spoiled sweet clover C3, 31methylene-bis-(4 hydroxy-coumarin) which prolongs coagulation and prothrombin time of 120 blood: Preliminary report of experiments and clinical studies. Proc. Staff Meet. Mayo Clinic 16, 388-395
4. Andrew M, Marzinotto V, Massicotte P et al. Heparin therapy in pediatric patients: A prospective cohort study. Pediatr. Res. 35(1), 78-83 (1994).
5. Schechter T, Finkelstein Y, Ali M et al. Unfractionated heparin dosing in young infants: Clinical outcomes in a cohort monitored with anti-factor Xa levels. J. Thromb. Haemost. 10(3), 368-374
6. Monagle P, Chan AKC, Goldenberg NA et al. Antithrombotic therapy in neonates and children: Antithrombotic therapy and prevention of thrombosis, 9th Ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(Suppl. 2), e737S-e801S (2012).
7. Merli G, Spiro TE, Olsson CG et al.; Enoxaparin Clinical Trial Group. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann. Intern. Med. 134(3), 191-202 (2001).
8. van Dongen CJ, MacGillavry MR, Prins MH. Once versus twice daily LMWH for the initial treatment of venous thromboembolism. Cochrane Database Syst. Rev. 3, CD003074 (2005).
9. Schobess R, Düring C, Bidlingmaier C, Heinecke A, Merkel N, Nowak-Göttl U. Long-term safety and efficacy data on childhood venous thrombosis treated with a low molecular weight heparin: An open-label pilot study of once-daily versus twice-daily enoxaparin administration. Haematologica 91(12), 1701-1704 (2006).
10. O'Brien SH, Lee H, Ritchey AK. Once-daily enoxaparin in pediatric thromboembolism: A dose finding and pharmacodynamics/pharmacokinetics study. J. Thromb. Haemost. 5(9), 1985-1987
11. Laposata M, Green D, Van Cott EM, Barrowcliffe TW, Goodnight SH, Sosolik RC. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: The clinical use and laboratory monitoring of lowmolecular- weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch. Pathol. Lab. Med. 122(9), 799-807 (1998).
12. Maureen A, De Veber G. Pediatric Thromboembolism and Stroke Protocols. B.C. Decker, ON, Canada (1997).
13. Sanderink GJ, Le Liboux A, Jariwala N et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin. Pharmacol. Ther. 72(3), 308-318 (2002).
14. Punzalan RC, Hillery CA, Montgomery RR, Scott CA, Gill JC. Low-molecular-weight heparin in thrombotic disease in children and adolescents. J. Pediatr. Hematol. Oncol. 22(2), 137-142 (2000).
15. Trame MN, Mitchell L, Krümpel A, Male C, Hempel G, Nowak-Göttl U. Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: A cohort study. J. Thromb. Haemost. 8(9), 1950-1958 (2010).
16. Laporte S, Mismetti P, Piquet P, Doubine S, Touchot A, Decousus H. Population pharmacokinetic of nadroparin calcium (Fraxiparine) in children hospitalised for open heart surgery. Eur. J. Pharm. Sci. 8(2), 119-125 (1999).
17. Massicotte P, Julian JA, Marzinotto V et al. Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin-sodium) in pediatric patients. Thromb. Res. 109(2-3), 93-99 (2003).
18. Bara L, Planes A, Samama MM. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery. Br. J. Haematol. 104(2), 230-240 (1999).
19. Ellison J, Walker ID, Greer IA. Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy. BJOG 107(9), 1116-1121
20. Crowther MA, Spitzer K, Julian J et al. Pharmacokinetic profile of a lowmolecular weight heparin (reviparin
21. in pregnant patients. A prospective cohort study. Thromb. Res. 98(2), 133-138
22. Hull RD, Raskob GE, Pineo GF et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N. Engl. J. Med. 326(15), 975-982 (1992).
23. Simonneau G, Sors H, Charbonnier B et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N. Engl. J. Med. 337(10), 663-669 (1997).
24. Kuhle S, Massicotte P, Dinyari M et al. Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events. Thromb. Haemost. 94(6), 1164-1171
25. Nohe N, Flemmer A, Rümler R, Praun M, Auberger K. The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: A report on 48 cases. Eur. J. Pediatr. 158(Suppl. 3), S134-S139 (1999).
26. Choay J, Petitou M, Lormeau JC, Sinaÿ P, Casu B, Gatti G. Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem. Biophys. Res. Commun. 116(2), 492-499 (1983).
27. Young G, Yee DL, O'Brien SH, Khanna R, Barbour A, Nugent DJ. FondaKIDS: A prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age. Pediatr. Blood Cancer 57(6), 1049-1054
28. Argatroban Injection®, prescribing information. GlaxoSmithKline, Research Triangle Park, NC, USA (2008).
29. Young G, Boshkov LK, Sullivan JE et al. Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: An open-label, safety, efficacy, and pharmacokinetic study. Pediatr. Blood Cancer 56(7), 1103-1109 (2011).
30. Madabushi R, Cox DS, Hossain M et al. Pharmacokinetic and pharmacodynamic basis for effective argatroban dosing in pediatrics. J. Clin. Pharmacol. 51(1), 19-28
31. Young G, Tarantino MD, Wohrley J, Weber LC, Belvedere M, Nugent DJ. Pilot dose-finding and safety study of bivalirudin in infants <6 months of age with thrombosis. J. Thromb. Haemost. 5(8), 1654-1659 (2007).
32. • Pharmacodynamic study of bivalirudin in children. 31 Forbes TJ, Hijazi ZM, Young G et al. Pediatric catheterization laboratory anticoagulation with bivalirudin. Catheter. Cardiovasc. Interv. 77(5), 671-679